V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Dynavax Technologies Executive Compensation (FY24)

DVAX · Executive and director compensation, fiscal 2022 to 2024

The paid brief on Dynavax Technologies

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (DEF 14A): April 17, 2025
3 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Dynavax Technologies brief$1,500Get the executive brief
253 figures on this page, cited to the filing that reported them. See the citations
Chief executive, fiscal 2024
◇
Ryan Spencer

More on Dynavax Technologies

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Ryan Spencer: $5,810,736 → $8,210,775 (41.3% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Dynavax Technologies' chief executive and what were they paid?
Total compensation for Ryan Spencer, Chief Executive Officer and Director, came to $8,210,775 in fiscal 2024. Compared with the $5,810,736 reported for fiscal 2023, Spencer's total was 41.3% higher.
Which companies are in Dynavax Technologies' peer group?
The disclosed peer group names Acadia Pharmaceuticals, Inc., Agenus, Inc., Alector, Inc., Amicus Therapeutics, Inc. and Collegium Pharmaceuticals, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Novack
President and Chief Operating Officer
◇—◇◇◇—◇◇
Kelly MacDonald
Senior Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Robert Janssen
Chief Medical Officer and Senior Vice President
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ryan Spencer
Chief Executive Officer and Director
◇—◇◇◇—◇◇
David Novack
President and Chief Operating Officer
◇—◇◇◇—◇◇
Kelly MacDonald
Senior Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Robert Janssen
Chief Medical Officer and Senior Vice President
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ryan Spencer
Chief Executive Officer and Director
◇—◇◇◇—◇◇
David Novack
President and Chief Operating Officer
◇—◇◇◇—◇◇
John Slebir
Senior Vice President and General Counsel
◇—◇◇◇—◇◇
Kelly MacDonald
Senior Vice President and Chief Financial Officer
◇◇◇◇◇—◇◇
Robert Janssen
Chief Medical Officer and Senior Vice President
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
David F. NovackOPTION◇——◇—◇◇
David F. Novack—◇——◇——◇
David F. NovackPSU◇◇◇—◇—◇
John L. SlebirOPTION◇——◇—◇◇
John L. Slebir—◇——◇——◇
John L. SlebirPSU◇◇◇—◇—◇
Kelly MacDonaldPSU◇◇◇—◇—◇
Kelly MacDonald—◇——◇——◇
Kelly MacDonaldOPTION◇——◇—◇◇
Robert JanssenPSU◇◇◇—◇—◇
Robert JanssenOPTION◇——◇—◇◇
Robert Janssen—◇——◇——◇
Ryan SpencerPSU◇◇◇—◇—◇
Ryan Spencer—◇——◇——◇
Ryan SpencerOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Robert JanssenOption◇—◇2/15/2031
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇2/9/2029
Option◇—◇2/15/2030
PSU◇◇——
John SlebirPSU◇◇——
Option◇—◇2/15/2030
RSU◇◇——
Option◇—◇2/14/2031
PSU◇◇——
RSU◇◇——
Option◇—◇2/9/2029
PSU◇◇——
David NovackRSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇2/15/2030
RSU◇◇——
PSU◇◇——
Option◇—◇2/9/2029
Option◇—◇2/2/2028
Kelly MacDonaldPSU◇◇——
Option◇—◇2/9/2029
PSU◇◇——
RSU◇◇——
Option◇—◇2/15/2031
RSU◇◇——
PSU◇◇——
Option◇—◇2/15/2030
Ryan SpencerPSU◇◇——
Option◇—◇2/15/2030
PSU◇◇——
RSU◇◇——
Option◇—◇2/14/2031
RSU◇◇——
PSU◇◇——
Option◇—◇2/9/2029
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Scott Myers
Board chair
◇◇◇———◇
Peggy V. Phillips
◇◇◇———◇
Peter R. Paradiso
◇◇◇———◇
Julie Eastland
◇◇◇———◇
Daniel L. Kisner
◇◇◇———◇
Elaine Sun
◇◇◇———◇
Francis R. Cano
◇◇◇———◇
Brent MacGregor
◇◇◇———◇
Ryan Spencer, Emilio Emini and Lauren Silvernail served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Acadia Pharmaceuticals, Inc. ACAD
  • Agenus, Inc. AGEN
  • Alector, Inc. ALEC
  • Amicus Therapeutics, Inc. FOLD
  • Collegium Pharmaceuticals, Inc. COLL
  • Corcept Therapeutics, Inc. CORT
  • Eagle Pharmaceuticals, Inc. EGRX
  • Exelixis, Inc. EXEL
  • Fibrogen, Inc. symbol not shown
  • Harmony Biosciences, Inc. HRMY
  • Ionis Pharmaceuticals, Inc. IONS
  • Ironwood Pharmaceuticals, Inc. IRWD
  • Mannkind Corp. MNKD
  • Novavax, Inc. NVAX
  • Pacira BioSciences, Inc. PCRX
  • PTC Therapeutics, Inc. PTCT
  • Supernus Pharmaceuticals, Inc. SUPN
  • Travere Therapeutics, Inc. TVTX
  • Vaxcyte, Inc. PCVX
  • Vir Biotechnology, Inc. VIR
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Dynavax Technologies files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Dynavax Technologies disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Dynavax Technologies sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Dynavax Technologies' disclosed peer group is defensible, who names Dynavax Technologies back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
253 figures on this page, cited to the filing that reported them.
253 cited to the filing

Documents cited

  1. 0000930413-25-001273
    DIRECTOR COMPENSATION TABLE & · Director Compensation table · OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END · Outstanding Equity Awards at Fiscal Year End · and 1 more section
  2. 0001140361-24-019367
    SUMMARY COMPENSATION TABLE
  3. 0001140361-23-018236
    SUMMARY COMPENSATION TABLE
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Dynavax Technologies executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/DVAX (accessed 2026).
Short form: data: Velarion

The paid brief for Dynavax Technologies

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Dynavax Technologies and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Dynavax Technologies discloses

The companies named in DVAX's own disclosed peer group.

Acadia Pharmaceuticals, Inc.Agenus, Inc.Alector, Inc.Amicus Therapeutics, Inc.Collegium Pharmaceuticals, Inc.Corcept Therapeutics, Inc.Eagle Pharmaceuticals, Inc.Exelixis, Inc.Harmony Biosciences, Inc.Ionis Pharmaceuticals, Inc.Ironwood Pharmaceuticals, Inc.Mannkind Corp.Novavax, Inc.Pacira BioSciences, Inc.PTC Therapeutics, Inc.Supernus Pharmaceuticals, Inc.Travere Therapeutics, Inc.Vaxcyte, Inc.Vir Biotechnology, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy